Novo Nordisk A/S: Director/PDMR Shareholding

BAGSVAERD, DENMARK, Nov 02 (MARKET WIRE) --
Trading in Novo Nordisk shares by board members, executives and
associated persons as reported to Novo Nordisk on 30 October 2009

In
accordance with Section 28a of the Danish Securities Trading Act, Novo
Nordisk is required on a daily basis to publish trading in Novo Nordisk
shares by the company's board members, executives and their associated
persons as reported by those persons to Novo Nordisk.

Please find below a statement of such trading in shares issued by Novo
Nordisk.

+---------------------------------------------------------------+
| Name | Mads Krogsgaard Thomsen |
|-----------------------------+---------------------------------|
| Reason for reporting | Chief Science Officer |
|-----------------------------+---------------------------------|
| Financial instrument and ID | Novo Nordisk B DK006010261 |
| code | |
|-----------------------------+---------------------------------|
| Type of transaction | Exercise of options (purchase of|
| | shares) |
|-----------------------------+---------------------------------|
| Date of transaction | 30 October 2009 |
|-----------------------------+---------------------------------|
| Place of transaction | NASDAQ OMX Copenhagen |
|-----------------------------+---------------------------------|
| Volume of transaction | 500 shares |
|-----------------------------+---------------------------------|
| Total value of transaction | DKK 48,750 |
+---------------------------------------------------------------+

+---------------------------------------------------------------+
| Name | Mads Krogsgaard Thomsen |
|----------------------------------+----------------------------|
| Reason for reporting | Chief Science Officer |
|----------------------------------+----------------------------|
| Financial instrument and ID code | Novo Nordisk B DK006010261 |
|----------------------------------+----------------------------|
| Type of transaction | Sale of shares |
|----------------------------------+----------------------------|
| Date of transaction | 30 October 2009 |
|----------------------------------+----------------------------|
| Place of transaction | NASDAQ OMX Copenhagen |
|----------------------------------+----------------------------|
| Volume of transaction | 500 shares |
|----------------------------------+----------------------------|
| Total value of transaction | DKK 158,000 |
+---------------------------------------------------------------+

Definitions and background information:

Publication

Publication shall take place the day after Novo Nordisk receives
sufficient information on the trading. Publication is only required when
the total amount of transactions of a specific board member/executive and
his/her associated persons in any one calendar year has reached 5,000
euros.

Who are board members, executives and associated persons?

Board members and executives are members of the Board of Directors and
Executive Management, respectively, of Novo Nordisk A/S. Associated
persons are defined as the following persons associated to a board
member/executive: 1) spouse or cohabitant, 2) children under the age of
18 years, 3) relatives defined as brothers, sisters, parents,
grandparents etc, children, grandchildren etc who have shared the same
household with a board member/executive for at least one year, and 4) any
legal person, including a company, a foundation or a partnership, which
is controlled directly or indirectly by a board member/executive and/or a
person mentioned in 1)-3), or to which a board member/executive and/or a
person mentioned in 1)-3) has managerial responsibilities or economic
interests substantially equivalent to the legal person.

What is trading/transaction?

Trading is any kind of transaction, including shares purchased or
otherwise acquired, shares sold or otherwise disposed, gifts, mortgages
and grants and exercise of options, but not heritage.

What is financial instrument and ID code?

Financial instrument includes shares listed on the NASDAQ OMX Copenhagen
and London Stock Exchange as well as ADRs listed on New York Stock
Exchange, except for ADRs held in 401(k) retirement plan by US-based
employees. The ID code is the code (ISIN DK006010261) of the Novo Nordisk
share on the NASDAQ OMX Copenhagen, the code (NVOB) on London Stock
Exchange or the code (NVO) on New York Stock Exchange.

What is date and place of transaction?

Date of transaction is the actual transaction date. The place of
transaction is the actual place of transaction, ie NASDAQ OMX Copenhagen,
London Stock Exchange or New York Stock Exchange.

What is volume and value of transaction?

The volume of transaction is the number of shares (of DKK 1 nominal
value) or other financial instruments traded. The transaction value is
the number of shares traded multiplied by the transaction price. The
exchange rate of the Danish Central Bank (Nationalbanken) on the date of
transaction is used for calculating the transaction value in DKK in case
of shares traded on London Stock Exchange and ADRs listed on New York
Stock Exchange.

Novo Nordisk is a healthcare company and a world leader in diabetes care.
In addition, Novo Nordisk has a leading position within areas such as
haemostasis management, growth hormone therapy and hormone replacement
therapy. Novo Nordisk manufactures and markets pharmaceutical products
and services that make a significant difference to patients, the medical
profession and society. With headquarters in Denmark, Novo Nordisk
employs over 29,000 employees in 81 countries, and markets its products
in 179 countries. Novo Nordisk's B shares are listed on the stock
exchanges in Copenhagen and London. Its ADRs are listed on the New York
Stock Exchange under the symbol 'NVO'. For more information, visit
novonordisk.com.

Company Announcement no 66 / 2009

This announcement was originally distributed by Hugin. The issuer is
solely responsible for the content of this announcement.

Copyright Copyright Hugin AS 2009. All rights reserved.

For further information please contact:

Media:

Elin K Hansen
Tel: (+45) 4442 3450
E-mail: Email Contact

In North America:
Sean Clements
Tel: (+1) 609 514 8316
E-mail: Email Contact

Investors:

Mads Veggerby Lausten
Tel: (+45) 4443 7919
E-mail: Email Contact

Kasper Roseeuw Poulsen
Tel: (+45) 4442 4471
E-mail: Email Contact

In North America
Hans Rommer
Tel: (+1) 609 919 7937
E-mail: Email Contact

Copyright 2009, Market Wire, All rights reserved.

-0-